Tag:
Cipla
Latest Headlines
Latest Headlines
Cipla partnership plans $50 million expansion in Uganda
A partnership between Quality Chemical Industries and Cipla is preparing to expand a manufacturing operation in Luzira, Uganda, where it makes HIV drugs.
India's drug regulator says it will clean up its act
India's health agency has vowed that its top drug regulator will clean up its act, saying it will cinch up oversight rules for letting drugs on the market.
Indian panel accuses Big Pharma of colluding with regulators
An Indian government report has hit the domestic pharma business like a whirlwind--and sucked Big Pharma into the fury.
Bayer slams Indian government, Cipla on Nexavar copies
Since the Indian government yanked its exclusivity on the cancer drug, the German company is fighting back.
India's Cipla puts fire-sale prices on cancer drugs
Indian genericsmaker Cipla will sell its copies of cancer drugs for a fraction of their branded counterparts.
Drugs made by Sun Pharma, Cipla recalled in U.S.
Two of India's top drugmakers are grappling with product recalls after regulators in the U.S. spotted signs of impurities in their drugs.
India's Emcure to manufacture Roche's Herceptin, MabThera
Roche ( $RHHBY ) is turning to an Indian pharmaceutical contract manufacturer, Emcure Pharmaceuticals, to produce its biologic drugs Herceptin and MabThera for India and other developing markets.
Indian regulators, alleging overpricing, demand $86M from Cipla
Another company is in trouble over allegations of overcharging the government for its drugs. This time, the company is Cipla , and it's received a rather stern note from India's National Pharmaceutical Pricing Authority, which is demanding that the drugmaker pay $86 million for overcharging for certain meds, according to Reuters .
No more working Saturdays at exports-minded Cipla
Why isn't Cipla as big as Ranbaxy Laboratories ? That's the central question of an Economic Times story profiling Chairman Yusuf Hamied and his company's recent changes. After years of promoting from
Cipla eyes alliances to grow in emerging markets
Takeda may well be eyeing a buyout to expand in India, but Cipla, one of its supposed targets, has its own emerging markets plans. The Indian company, like virtually every ambitious drugmaker these
